2002
Week 3
Oxford GlycoSciences has five applications concerned with
nucleic acids and peptides, specifying likely utility in such conditions as neurological disorders, asthma, breast cancer and ErbB2-related cancer. Over the past five years the company has had an average of only three international patent applications published each year, but the indications are that the rate of filing is now increasing.
current-patents.com
Week 4
Oxford GlycoSciences has eight further applications in the
series first mentioned last week, relating to nucleotides and polypeptides. The additional filings extend therapeutic coverage to conditions such as T-cell leukemia, angiogenesis, and breast, liver and prostate cancer, and OGS clearly has a major patent filing program under way. A similar burst of filing activity in February 2000, involving parallel US applications in some instances, resulted in a series of ten PCT applications published 18 months later (WO0162784, etc).
current-patents.com
Week 16
Substantial series of initial filings from Novartis, Glaxo
and AstraZeneca dominate the initial patent applications
submitted to the UK Patent Office during the first week of
March 2002; there are also multiple applications from such
specialist companies as Inpharmatica, British Biotech, Cipla and Oxford Glycosciences. Our informal comments on these and other recent applications appear elsewhere in this issue (see "Additional Information" list overleaf).
current-patents.com
Week 32
BioInvent International AB has an application relating to
treatment, diagnosis and imaging of disease. The company's
core technology is the antibody library known as n-CoDeR.
CellControl, GSK, OGS and Pharmacia are among those
collaborating in the exploitation of this platform, and the Lund-based company has recently announced acquisition of patent rights from Thymon LLC of New Jersey in relation to HIV therapy.
current-patents.com
Week 42
Oxford Glycosciences can also be seen this week with a claim for new “Toxicity markers”. The company has entered into a collaboration with the Center for Drug Evaluation and Research (part of the US FDA). This work will involve the use of serum proteins as markers for drug induced toxicity, intended to develop a beneficial product that can be used for monitoring and reducing toxicity during clinical trials and also after a drug has been approved.
current-patents.com
Week 43
New therapeutic drugs do not form a large proportion of the subject matter of this week’s UK priority applications. Proteins involved in carcinoma, particularly pancreatic cancer, are the subject of three Oxford GlycoSciences priority applications filed in September. Four applications have been filed by Anthony Austin, for aspects of transmissible spongiform encephalopathy, including a vaccine and a brain antibody test. The applicant has authored several articles in the Veterinary Record on the subject and filed a number of UK priority applications, but no specifications appear to have been published to date.
current-patents.com
Week 46
Oxford GlycoSciences and Bayer have published two joint
applications this week, they disclose proteins for use in
therapy. In a recent press release Oxford GlycoSciences
announced that it had identified protein targets for Bayer
relating to asthma and Chronic Obstructive Pulmonary Disease (COPD).
Week 48
Oxford GlycoSciences has been collaborating with Pfizer for several years on the identification of disease-specific proteins as potential diagnostics, clinical markers and targets for the development of drugs, utlizing OGS' proteomics technology. However, two of the company’s three latest UK priority applications relate to proteins involved in therapy and are filed jointly with Bayer.
current-patents.com
John McCarthy |
